Education
About Us
Working with TipRanks
Follow Us
MTRA - ETF AI Analysis
Top Page
Invesco International Growth Focus ETF (MTRA)
Rating:61Neutral
Price Target:―
Positive Factors
Strong Top Holdings
Several top holdings, such as Alibaba and ASML Holding NV, have delivered strong year-to-date performance, supporting the ETF's overall returns.
Global Diversification
The ETF invests across multiple countries, including the USA, UK, France, and Japan, reducing exposure to risks in any single region.
Balanced Sector Exposure
The fund is diversified across sectors like Industrials, Health Care, and Technology, helping to mitigate risks from sector-specific downturns.
Negative Factors
Moderate Expense Ratio
The ETF's expense ratio of 0.54% is higher than some low-cost alternatives, which could slightly reduce net returns over time.
Underperforming Holdings
Some holdings, such as Sartorius Stedim Biotech and Resmed, have shown weaker year-to-date performance, which may drag on overall returns.
Limited Emerging Market Exposure
The ETF has minimal exposure to emerging markets, which could limit potential growth opportunities in faster-growing economies.
MTRA vs. SPDR S&P 500 ETF (SPY)
AUM157.23M
RegionGlobal Ex-U.S.
Expense Ratio0.54%
Beta1.22
IssuerInvesco
Inception DateJun 11, 2025
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume23,318
30 Day Avg. Volume22,038
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
29.75Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering48
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MTRA Summary
The Invesco International Growth Focus ETF (MTRA) is a fund that invests in companies outside the U.S., focusing on businesses with strong growth potential. It includes well-known global companies like ASML Holding NV and Alibaba, and covers industries such as technology, healthcare, and industrials. With exposure to markets in Europe, Asia, and North America, this ETF is a good option for investors looking to diversify their portfolio and tap into international growth opportunities. However, since it invests heavily in global markets, its performance can be affected by economic conditions and currency fluctuations in other countries.
How much will it cost me?The Invesco International Growth Focus ETF (MTRA) has an expense ratio of 0.54%, which means you’ll pay $5.40 per year for every $1,000 invested. This is higher than average because the fund is actively managed, requiring more research and analysis to select stocks. Active management often leads to higher costs compared to passively managed funds that track an index.
What would affect this ETF?The Invesco International Growth Focus ETF (MTRA) could benefit from global economic recovery and increased demand for innovative technologies, healthcare advancements, and industrial growth, as these sectors make up a significant portion of its holdings. However, potential risks include geopolitical tensions, regulatory changes in key regions, and currency fluctuations, which could negatively impact the performance of its international investments. Additionally, rising interest rates or economic slowdowns in major markets could challenge growth-focused companies in the ETF.
MTRA Top 10 Holdings
The Invesco International Growth Focus ETF (MTRA) leans heavily into global growth opportunities, with a notable concentration in industrials and healthcare. Siemens is steady, benefiting from solid revenue growth, while AstraZeneca’s rising performance is bolstered by product approvals and strategic expansions. On the flip side, Alibaba’s mixed momentum and cash flow challenges are holding the fund back despite its long-term AI investments. ASML is a bright spot in the technology sector, driving gains with robust revenue growth, though its high valuation tempers enthusiasm. Overall, the fund’s global ex-U.S. focus offers a diverse mix of rising stars and lagging names across innovative sectors.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Siemens | 3.57% | $5.64M | €184.83B | 25.03% | 74 Outperform | |
| AstraZeneca | 3.38% | $5.35M | £211.95B | 30.80% | 80 Outperform | |
| Booking Holdings | 3.36% | $5.30M | $173.86B | 6.79% | 63 Neutral | |
| Epam Systems | 3.35% | $5.29M | $11.56B | -13.21% | 70 Neutral | |
| Alibaba | 3.25% | $5.13M | $356.64B | 77.31% | 68 Neutral | |
| Resmed | 3.17% | $5.00M | $35.75B | 6.70% | 76 Outperform | |
| Dollarama | 3.09% | $4.88M | C$55.69B | 52.30% | 71 Outperform | |
| ASML Holding NV | 3.08% | $4.87M | €344.40B | 31.20% | 76 Outperform | |
| Sartorius Stedim Biotech | 2.99% | $4.72M | €19.88B | 12.09% | 61 Neutral | |
| Tencent Holdings | 2.96% | $4.68M | HK$5.56T | 48.30% | 75 Outperform |
MTRA Technical Analysis
Positive
―
Price Trends
25.95
Positive
25.61
Positive
Market Momentum
0.08
Negative
55.68
Neutral
22.73
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MTRA, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 25.96, equal to the 50-day MA of 25.95, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 55.68 is Neutral, neither overbought nor oversold. The STOCH value of 22.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MTRA.
MTRA Peer Comparison
Comparison Results
Performance Comparison
MTRA
Invesco International Growth Focus ETF
26.19
1.09
4.34%
APIE
ActivePassive International Equity ETF
―
―
―
CGIC
Capital Group International Core Equity ETF
―
―
―
WCMI
First Trust WCM International Equity ETF
―
―
―
MFSI
MFS Active International ETF
―
―
―
IDVO
Amplify International Enhanced Dividend Income ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents